&#34;The Stock God of Capitol Hill&#34; has impressive sales power.
After former U.S. House Speaker Nancy Pelosi made a significant bet, AI healthcare concept stock Tempus AI saw its stock price soar by 35.5% on Tuesday, marking its best historical performance.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/157a1368-8d47-40dd-92c0-a8c48e2d11ef.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/157a1368-8d47-40dd-92c0-a8c48e2d11ef.png"/>
According to the latest disclosed trading records of congressional members, Pelosi purchased 50 call options for Tempus AI expiring in January 2026, with a strike price of $20 on January 14.
On the day of Pelosi's trade, Tempus AI's stock closed below $32, but by Tuesday's close, it had surged to $47.64, an increase of nearly 50%.
Pelosi's husband owns a venture capital firm, and she is one of the most active traders in Washington. In 2023, an ETF tracking investments by congressional Democrats was listed under the ticker &#34;NANC,&#34; which undoubtedly recognizes Pelosi's investment reputation.
Tempus AI was founded in 2015 and focuses on applying artificial intelligence technology in the field of precision medicine, using data and AI to enhance cancer treatment and improve patient outcomes.
Since its IPO in June 2024, Tempus AI's stock price has been volatile, reaching nearly $80 per share in November before significantly dropping, with its market value shrinking by more than half. &#34;Wood Sister&#34; Cathie Wood bought 30,000 shares before the October earnings report and has continued to buy since.
In addition to the endorsement from the &#34;Stock God of Capitol Hill,&#34; Tempus AI's new product has also gained recognition in the capital markets.
On Tuesday morning local time, Tempus AI launched an AI-driven personal health assistant application—olivia, aimed at enhancing patients' health management capabilities by centralizing users' health data on one platform and providing actionable insights through advanced AI.
According to the company's press release, olivia can integrate with Apple Watch and Google Fit to track users' daily health status, summarize their clinical history, and transcribe doctors' appointment records. Tempus CEO Eric Lefkofsky emphasized that olivia is not just an organizer of information but an &#34;active partner&#34; in patient health management.
The launch of olivia has triggered a strong market reaction, with Tempus's stock achieving its largest single-day gain since its listing in June of last year.
This market reaction may reflect a shift in Wall Street's narrative regarding AI. Since 2022, core companies in AI infrastructure have been the main beneficiaries of the AI boom. However, Goldman Sachs predicted in November last year that the AI revolution would enter its &#34;third phase&#34; this year, at which point more types of companies would see substantial contributions from AI to their revenues and profits. In particular, software companies are expected to benefit significantly as they launch AI assistants like olivia

Since Pelosi bought call options, Tempus AI's stock price has risen nearly 50%. Tempus AI focuses on applying artificial intelligence technology in the field of precision medicine and launched an AI-driven personal health assistant app on Tuesday

- Following former House Speaker Nancy Pelosi's significant investment, Tempus AI stock surged 35.5%, marking its best performance to date.  
- Pelosi purchased 50 call options for Tempus AI, which saw its stock price rise from below $32 to $47.64 within days, reflecting strong market confidence.  
- The launch of Tempus AI's new AI-driven health assistant, olivia, further boosted the stock, indicating a shift in Wall Street's perception of AI's potential impact on various sectors.

"The Congress Hill Stock God" buys Call, this AI stock soars 35%